LONDON — GSK said Tuesday it would purchase Bellus Health for $2 billion, adding a promising chronic cough drug to its pipeline.
The all-cash deal values Bellus, based in Laval, Canada, at $14.75 a share, roughly double Monday’s closing stock price.
STAT+: GSK to buy Bellus Health for $2 billion, gaining chronic cough drug
GSK said Tuesday it would purchase Bellus Health for $2 billion, adding a promising chronic cough drug to its pipeline.